| Page 997 | Kisaco Research

Emmanuel Gougé

This Global Biologics Cell and Gene Conference has been an extremely good forum for sharing views and address hop topics within the industry, I am glad I could spend the two days last week in Brussels with such a group of specialists. I am certainly looking forward to the next edition.

Emanuele Degortes

I really enjoyed participating in the Global Cell, Gene and Cell Therapy Legal Summit. The intimate format allowed for a good level of discussion and networking opportunities with representatives from other companies and the content of the discussion was highly relevant to my day-to-day activities.

Christof Bull

I really enjoyed the event. It was a great agenda with topics from different areas relevant to the biopharma industry. I felt that I had the opportunity to look beyond my day to day work. The speakers and discussions panels were excellent. The location was nice with good networking opportunities. A reception at the end of the event would have further improved the possibilities to network.

Xisca Borrás

It was a highly specialised conference where very interesting topics of particular relevance were discussed by experts in the field.  Format, location and organisation could not have been better, with multiple networking opportunities.

 

Matthew Jones

Partner
EIP

Matthew has extensive experience of acting in large scale UK and multi-jurisdictional patent litigation. Matthew has acted in litigation relating to a wide range of technologies, including pharmaceuticals, biotechnology, optics, mechanical devices, electronics, telecommunications, and cryptography.

Before joining EIP, Matthew worked as Senior Counsel for Teva Pharmaceuticals Europe. During this time Matthew managed high-profile litigation in the UK, Germany, France, and the Netherlands, including Generics [UK] Ltd v Yeda & Teva, which related to the blockbuster drug Copaxone®.

Read full bio

Matthew Jones

Partner
EIP

Matthew Jones

Partner
EIP

Matthew has extensive experience of acting in large scale UK and multi-jurisdictional patent litigation. Matthew has acted in litigation relating to a wide range of technologies, including pharmaceuticals, biotechnology, optics, mechanical devices, electronics, telecommunications, and cryptography.

Before joining EIP, Matthew worked as Senior Counsel for Teva Pharmaceuticals Europe. During this time Matthew managed high-profile litigation in the UK, Germany, France, and the Netherlands, including Generics [UK] Ltd v Yeda & Teva, which related to the blockbuster drug Copaxone®.

Matthew has a degree in Biochemistry from Bristol University and a PhD in Biochemistry (specialising in quantum enzymology) from Leicester University.